Alnylam Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Alnylam Pharmaceuticals, Inc. reported quarterly adjusted earnings of $15.72​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $2.11. The mean expectation of twenty seven analysts for the quarter was for earnings of $1.62 per share. Wall Street expected results to range from 86 cents to $2.24 per share.

• Revenue rose 16.7% to $1.46 billion from a year ago; analysts expected $1.43 billion.

• Alnylam Pharmaceuticals, Inc.'s reported EPS for the quarter was $15.72​.

• The company reported quarterly net income of $2.17 billion.

• Alnylam Pharmaceuticals, Inc. shares had fallen by 5.8% this quarter and lost 41.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.2% in the last three months.​

• In the last 30 days, seven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Alnylam Pharmaceuticals, Inc. is $349.50, about 33.5% above its last closing price of $232.40

This summary was machine generated from LSEG data October 29 at 07:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)